Analyst Andrew Berens works at LEERINK and is focused on Healthcare, Basic Materials sectors with 420 price targets and ratings documented since 2014 spanning on 31 stocks. Previously, Andrew Berens worked at MORGAN STANLEY. Analyst's average stock valuation to be materialised ratio is 49.72% with an average time for price targets to be met of 155.63 days.
Most recent stock forecast was given on BGNE, BeiGene, Ltd at 20-Jan-2023.
Andrew Berens best performing recommendations are on EPZM (EPIZYME, INC).
The best stock recommendation documented was for AGIO (AGIOS PHARMACEUTICALS, INC) at 2/23/2022. The price target of $30 was fulfilled within 2 days with a profit of $2.45 (8.89%) receiving and performance score of 44.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Sell
32
$1.28 (4.17%)
16
2 months 12 days ago
4/6 (66.67%)
$-3.45 (-9.48%)
149
Buy
37
$6.28 (20.44%)
33
5 months 24 days ago
8/14 (57.14%)
$11.15 (32.17%)
54
Buy
96
$65.28 (212.50%)
96
10 months 26 days ago
0/6 (0%)
$53.67 (151.78%)
Buy
67
$36.28 (118.10%)
61
11 months 4 days ago
7/12 (58.33%)
$25.77 (60.69%)
248
Buy
44
$13.28 (43.23%)
52
11 months 13 days ago
9/15 (60%)
$15.65 (33.73%)
157
